0 5 10 15 20 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg 0 5 10 15 20 0 4 8 12 16 20 24 All KSI-101 APEX KSI-101 in DME – Meaningful vision gains were achieved with all KSI-101 dose levels tested 69 While the 10 mg dose level seems to have an anatomical advantage, meaningful visual gains and bioactivity were observed in all dose levels Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes all available data by the 14-Jul-25 cutoff date. ETDRS Letters Weeks Treatment Phase Off-treatment Phase N values 2.5 mg 4 4 4 4 4 4 4 4 5 mg 4 4 4 3 3 3 3 3 10 mg 4 4 4 4 4 4 4 3 N values All KSI-101 12 12 12 11 11 11 11 10 ETDRS Letters Weeks Mean Change in BCVA by KSI-101 dose level Mean Change in BCVA all KSI-101 dose levels combined Treatment Phase Off-treatment Phase